Brokerages Anticipate Recro Pharma Inc (REPH) Will Post Quarterly Sales of $13.32 Million

Wall Street analysts expect that Recro Pharma Inc (NASDAQ:REPH) will announce $13.32 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Recro Pharma’s earnings, with estimates ranging from $13.30 million to $13.35 million. Recro Pharma posted sales of $17.36 million during the same quarter last year, which suggests a negative year-over-year growth rate of 23.3%. The firm is expected to report its next quarterly earnings results on Monday, March 5th.

According to Zacks, analysts expect that Recro Pharma will report full year sales of $13.32 million for the current fiscal year, with estimates ranging from $62.50 million to $66.14 million. For the next fiscal year, analysts expect that the business will report sales of $66.09 million per share, with estimates ranging from $63.60 million to $70.93 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research analysts that that provide coverage for Recro Pharma.

Recro Pharma (NASDAQ:REPH) last posted its earnings results on Thursday, November 9th. The specialty pharmaceutical company reported ($0.48) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.27. Recro Pharma had a negative net margin of 51.88% and a negative return on equity of 60.01%.

Several analysts recently weighed in on REPH shares. Zacks Investment Research cut shares of Recro Pharma from a “hold” rating to a “sell” rating in a research note on Wednesday, October 11th. Piper Jaffray Companies reissued a “buy” rating and issued a $11.00 price objective on shares of Recro Pharma in a research note on Friday, October 27th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $11.65.

Recro Pharma (REPH) traded up $0.04 during midday trading on Thursday, hitting $8.93. 163,894 shares of the company’s stock were exchanged, compared to its average volume of 87,771. The company has a current ratio of 1.59, a quick ratio of 1.35 and a debt-to-equity ratio of 0.50. Recro Pharma has a 12-month low of $5.81 and a 12-month high of $10.59. The company has a market capitalization of $170.80, a PE ratio of -4.08 and a beta of -0.50.

In other Recro Pharma news, major shareholder Scp Vitalife Partners (Israel) sold 12,964 shares of the company’s stock in a transaction on Wednesday, January 3rd. The shares were sold at an average price of $8.88, for a total transaction of $115,120.32. Following the sale, the insider now owns 734,269 shares of the company’s stock, valued at $6,520,308.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Scp Vitalife Partners Ii Lp sold 13,189 shares of the company’s stock in a transaction on Wednesday, December 27th. The shares were sold at an average price of $9.56, for a total transaction of $126,086.84. Following the sale, the insider now directly owns 2,243,064 shares in the company, valued at approximately $21,443,691.84. The disclosure for this sale can be found here. In the last three months, insiders sold 860,414 shares of company stock worth $8,289,916. 21.60% of the stock is currently owned by insiders.

A number of institutional investors and hedge funds have recently modified their holdings of REPH. OxFORD Asset Management LLP boosted its position in Recro Pharma by 364.3% during the second quarter. OxFORD Asset Management LLP now owns 203,430 shares of the specialty pharmaceutical company’s stock valued at $1,430,000 after acquiring an additional 159,619 shares during the last quarter. State Street Corp bought a new stake in Recro Pharma during the second quarter valued at $1,047,000. Northern Trust Corp boosted its position in Recro Pharma by 428.5% during the second quarter. Northern Trust Corp now owns 178,437 shares of the specialty pharmaceutical company’s stock valued at $1,254,000 after acquiring an additional 144,676 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in Recro Pharma by 787.4% during the second quarter. Dimensional Fund Advisors LP now owns 129,560 shares of the specialty pharmaceutical company’s stock valued at $911,000 after acquiring an additional 114,960 shares during the last quarter. Finally, JT Stratford LLC bought a new stake in Recro Pharma during the second quarter valued at $704,000. 61.55% of the stock is currently owned by institutional investors and hedge funds.

WARNING: “Brokerages Anticipate Recro Pharma Inc (REPH) Will Post Quarterly Sales of $13.32 Million” was posted by TrueBlueTribune and is owned by of TrueBlueTribune. If you are reading this piece on another site, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this piece can be viewed at https://www.truebluetribune.com/2018/01/21/brokerages-anticipate-recro-pharma-inc-reph-will-post-quarterly-sales-of-13-32-million.html.

About Recro Pharma

Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.

Get a free copy of the Zacks research report on Recro Pharma (REPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply